Chronic hepatitis C viral infection in patients with normal serum alanine aminotransferases

American Journal of Medicine

Volumn 107, Issue 6 SUPPL. 2, 1999, Pages 53-55

  Di Bisceglie, Adrian M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CONFERENCE PAPER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0033372622     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(99)00383-6     Document Type: Conference Paper

References (11)

1. Piton A., Poynard T., Imbert-Bismut F., et al. Factors associated with serum transaminase activity in healthy subjects consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC group . Hepatology. 27:1998;1213-1219.
2. Shakil A.O., Conry-Cantilena C., Alter H.J., et al. Volunteer blood donors with antibody to hepatitis C virus clinical, biochemical, virologic, and histologic features. The hepatitis C study group . Ann Intern Med. 123:1995;330-337.
3. Pouti C., Margini A., Stati T., et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology. 26:1997;1393-1398.
4. Sangiovanni A., Morales R., Spinzi G., et al. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels a pilot randomized controlled study . Hepatology. 27:1998;853-856.
5. Naito M., Hayashi N., Moribe T., et al. Hepatitis C viral quasispecies in hepatitis C virus carriers with normal liver enzymes and patients with type C chronic liver disease. Hepatology. 22:1995;407-412.
6. Mathurin P., Moussalli J., Cadranel J.F., et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology. 27:1998;868-872.
7. NIH Consensus Statement. Management of hepatitis C. Hepatology 1997;15:1-41.
8. Serfaty L., Chazouilleres O., Pawlotsky J.M., et al. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology. 110:1996;291-295.
9. Ideo G., Bellobuono A., Mondazzi L., et al. Alpha interferon treatment in chronic hepatitis C. Clin Exp Rheumatol. 13:(suppl 13):1995;S167-S173.
10. Orito E., Mizokami M., Suzuki K., et al. Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment. J Gastroenterol Hepatol. 12:1997;58-61.
11. Bacon BR, Rauscher JA, Smith-Wilkaitis NL, et al. Interferon-ribavirin combination is successful in eliminating hepatitis C virus in nonresponders to interferon alone including patients with normal aminotransferases. Hepatology 1998:28:372A. Abstract.